173 results about "Solid cancer" patented technology

The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provide methods of identifying inhibitors of tumorigenesis.

An IL-6 production inhibitor which comprises a hydroxamic acid derivative of formula (I)

(wherein all the symbols have the same meanings as defined in the specification), an equivalent thereof, a non-toxic salt thereof or a prodrug thereof as an active ingredient. Because of having an IL-6 production inhibitory activity, the compound of formula (I) may be useful for the prevention and/or treatment of various inflammatory diseases, sepsis, multiple myeloma, plasma cell leukemia, osteoporosis, cachexia, psoriasis, nephritis, renal cell carcinoma, Kaposi's sarcoma, rheumatoid arthritis, hypergammaglobulinemia (gammophathy), Castleman's disease, intra-atrial myxoma, diabetes, autoimmune disease, hepatitis, colitis, graft-versus-host disease, infectious diseases, endometriosis and solid cancer.

This invention relates generally to treatment of solid cancers. More particularly, the invention relates to a computer controlled patient positioning, immobilization, and repositioning method and apparatus used in conjunction with multi-field charged particle cancer therapy coordinated with patient respiration patterns and further in combination with charged particle beam injection, acceleration, extraction, and/or targeting methods and apparatus.

The invention relates generally to treatment of solid cancers. More particularly, the invention relates to a multi-field imaging and/or a multi-field charged particle cancer therapy method and apparatus coordinated with patient respiration via use of feedback sensors used to monitor and/or control patient respiration. Preferably, the multi-field imaging, such as X-ray imaging, and the charged particle therapy are performed on a patient in a partially immobilized and repositionable position. X-ray and/or proton delivery is timed to patient respiration via control of charged particle beam injection, acceleration, extraction, and/or targeting methods and apparatus.

The present invention relates generally to thienopyrimidine and thienopyridine class compounds and methods of use thereof. In particular embodiments, the present invention provides compositions comprising thienopyrimidine class compounds and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins (e.g., for the treatment of leukemia, solid cancers and other diseases dependent on activity of MLL1 and MLL2 or menin).

The invention relates generally to treatment of solid cancers. More particularly, the invention relates to enhancing synchrotron acceleration cycle usage efficiency by adjusting the synchrotron's acceleration cycle to correlate with a patient's respiration rate where efficiency refers to the duty cycle or the percentage of acceleration cycles used to deliver charged particles to the tumor. The system senses patient respiration and controls timing of negative ion beam formation, injection of charged particles into a synchrotron, acceleration of the charged particles, and extraction to yield delivery of the particles to the tumor at a predetermine period of the patient's respiration cycle. Independent control of charged particle energy and intensity is maintained during the timed irradiation therapy. Multi-field irradiation ensures efficient delivery of Bragg peak energy to the tumor while spreading ingress energy about the tumor.

A device and method of detection and treatment of a solid cancer tumor, for example prostate cancer. In a diagnostic method, ultrasound is used to extract a cancer tumor marker from interstitial fluid into a coupling medium. In a method for treating a solid tumor, ultrasound is used to deliver one or more drugs from the coupling medium directly to the site of the tumor.

The invention relates generally to treatment of solid cancers. More particularly, a method and apparatus for efficient radiation dose delivery to a tumor is described. Preferably, radiation is delivered through an entry point into the tumor and Bragg peak energy is targeted to a distal or far side of the tumor from an ingress point. Delivering Bragg peak energy to the distal side of the tumor from the ingress point is repeated from multiple rotational directions. Beam intensity is proportional to radiation dose delivery efficiency. The multi-field irradiation process with energy levels targeting the far side of the tumor from each irradiation direction provides even and efficient charged particle radiation dose delivery to the tumor. Preferably, the charged particle therapy is timed to patient respiration via control of charged particle beam injection, acceleration, extraction, and/or targeting methods and apparatus.

The invention relates to treatment of solid cancers and more particularly to a method and apparatus correlating proton beam intensity with proton delivery efficiency, optionally in a raster beam scanning system. The system induces betatron oscillation on the proton beam causing the beam to traverse an extraction material resulting in slowed protons and a feedback current proportional to the proton flux. A controller receives the desired intensity from an irradiation plan and the feedback current and adjusts the radio-frequency field in the radio-frequency cavity system to yield an intensity of the proton beam that matches the desired intensity from the irradiation plan. Preferably, the intensity of the proton beam correlates with radiation delivery efficiency. The system preferably operates in conjunction with a multi-field charged particle cancer therapy system, with charged particle beam injection, particle beam acceleration, multi-axis charged particle beam control, and/or targeting methods and apparatus.

An anticancer high-molecular precursor medicine C-Spacer-P, where P is high- molecular pectin, C is an anticancer medicine containing amino radical or hydroxy radical, and Spacer is the spacing radical, is prepared by bonding the amino or hydroxy of an anticancer medicine with the hydroxy, carboxy, or hydroxymethyl of high- molecular pectin via spacing radical. It is an injection suitable for the solid cancer, and cancerous ascites or hydrothorax.

The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.

Disclosed herein is a method for suppressing the growth of cancer cells in a mammal in need of such treatment comprising administering to said mammal a cancer cell suppressing amount of a diphenylmethylpiperazine represented by the following general formula [1]:wherein R represents:or a pharmaceutically acceptable salt thereof.Compared with conventional anticancer agents, these agents are less toxic and exert an excellent carcinostatic effect on various solid cancers. Moreover, these anticancer agents inhibit the proliferation of fibroblasts, which makes them efficacious against pulmonary fibrosis and proliferative keloid lesions.

The present invention provides a detecting instrument for early mammary cancer, skin cancer or other solid cancers. A temperature sensor of the detecting instrument is provided with at least one row of scanning probes which are uniformly arranged on a probe supporter through a comb shape. The temperature measuring range of temperature sensor is 0-45 DEG C. The head part of each scanning probe penetrates out of the probe supporter. A data transmission wire connected with tail part of each scanning probe is connected with a detecting host machine. The detecting host machine comprises the following components: a casing, a regulated power supply circuit, a data selecting switch module, keystrokes, a singlechip, a preamplifying module, an A/D converting module, a display and an alarm. The invention settles the technical problems of complicated detecting operation, high detecting expense and large detecting radiation in detecting operation of mammary cancer, skin cancer and other solid cancers. The detecting instrument can effectively eliminate various interferences in detection and has the advantages of reliable data, good repeatability, convenient use, quick detection, small volume, high automatization degree. The detecting instrument is a self-detecting device which is suitable for family and personal use for detecting early mammary cancer and other diseases.

The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.